This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Philips Respironics Announces Availability Of New Patient-Centric Solution For The Management Of Chronic Respiratory Insufficiency Diseases, BiPAP A40, On World COPD Day 2012

DÜSSELDORF, Germany, November 14, 2012 /PRNewswire/ --

BiPAP A40 is a new multi-modality bi-level ventilator featuring the first fully automatic ventilation mode, designed to support the smooth transition of treatment from hospital to home

Philips Respironics today announces the availability of the new bi-level ventilator BiPAP A40 [1] for the management of chronic respiratory insufficiency, a condition secondary to diseases such as obesity hypoventilation syndrome, chronic obstructive pulmonary disease (COPD) and neuromuscular disease for adult and pediatric patients (above 10 kg).

Launching on World COPD Day 2012 and being showcased this week at Medica 2012, the world's largest medical trade fair, the BiPAP A40 improves the management of chronic respiratory diseases by offering a range of unique benefits that facilitate the smoothest possible transition in the patient care pathway - from initial titration to hospital discharge, from home therapy to long-term follow-up.  

"Philips is proud to be able to provide access to new and innovative solutions that improve quality of care for respiratory patients - both in hospital and at home," comments Mats Dahlquist, general manager international, Philips Home Healthcare Solutions.

"One of the key benefits of the BiPAP A40 is an innovative ventilation mode called AVAPS-AE, which helps to guide clinicians during the initial titration of therapy, while maintaining comfort and improving efficacy for the patient. This new ventilation mode automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. AVAPS-AE mode also helps to guide clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance.

In addition to the introduction of AVAPS-AE, the BiPAP A40 features a unique battery module design which provides users with an enhanced level of autonomy that increases support when traveling, or in the case of a power shortage. Furthermore, the design incorporates an intuitive user interface and data management tools that allow clinicians to remotely access and review data about a user's therapy, adjusting it as necessary. This can help to reduce therapy drop out and the associated risk of hospital re-admission.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,851.23 -76.97 -0.43%
S&P 500 2,085.95 -3.51 -0.17%
NASDAQ 4,929.8650 -9.4620 -0.19%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs